Clinical Review Report (Sample)

Similar documents
CADTH RAPID RESPONSE REPORT: REFERENCE LIST Side Effect Free Chemotherapy for the Treatment of Cancer: Clinical Effectiveness

Service Line: Rapid Response Service Version: 1.0 Publication Date: January 21, 2019 Report Length: 5 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: October 30, 2018 Report Length: 7 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: June 12, 2018 Report Length: 5 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: March 5, 2018 Report Length: 5 Pages

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

CADTH Canadian Drug Expert Committee Recommendation

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 09, 2018 Report Length: 7 Pages

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

Service Line: Rapid Response Service Version: 1.0 Publication Date: April 4, 2018 Report Length: 14 Pages

CADTH COMMON DRUG REVIEW Pharmacoeconomic Review Report

Service Line: Rapid Response Service Version: 1.0 Publication Date: August 30, 2018 Report Length: 11 Pages

CADTH Canadian Drug Expert Committee Recommendation

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

Increasing Frequency of Self-Monitoring Blood Glucose Test Strips During Pregnancy: A Review of the Clinical and Cost- Effectiveness and Guidelines

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

Pharmacoeconomic Review Report

CADTH Canadian Drug Expert Committee Recommendation

CADTH Canadian Drug Expert Committee Recommendation

CADTH Canadian Drug Expert Committee Recommendation

CADTH Canadian Drug Expert Committee Recommendation

Common Drug Review Pharmacoeconomic Review Report

CADTH Canadian Drug Expert Committee Recommendation

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Benzydamine for Acute Sore Throat: A Review of Clinical Effectiveness and Guidelines

CADTH Optimal Use Report

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries

CADTH Therapeutic Review

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL

BRAF Targeted Therapy for Patients with Melanoma and Active Brain Metastases: A Review of Clinical Effectiveness

Common Drug Review Pharmacoeconomic Review Report

COMPUS Vol 2, Issue 8 December 2008

Clinical Review Report

CADTH RAPID RESPONSE REPORT: SUMMARY WITH CRITICAL APPRAISAL Nabilone for Chronic Pain Management: A Review of Clinical Effectiveness and Guidelines

Orthodontic Treatment for the Management of Pain or Impacted Teeth in Patients with Malocclusion: A Review of Clinical Effectiveness and Guidelines

DATE: 17 July 2012 CONTEXT AND POLICY ISSUES

CADTH TECHNOLOGY REVIEW Current Practice Analysis: Interventions for Insomnia Disorder

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

Service Line: Rapid Response Service Version: 1.0 Publication Date: October 18, 2017 Report Length: 20 Pages

CADTH HEALTH TECHNOLOGY ASSESSMENT Screening for Hepatitis C Virus: A Systematic Review

Common Drug Review Pharmacoeconomic Review Report

Insulin Pens in Acute Care Settings: Clinical Effectiveness, Cost- Effectiveness, and Guidelines

pan-canadian Oncology Drug Review Final Economic Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013

Service Line: Rapid Response Service Version: 1.0 Publication Date: February 15, 2017 Report Length: 15 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 04, 2018 Report Length: 47 Pages

Service Line: Rapid Response Service Version: 2.0 Publication Date: November 29, 2018 Report Length: 20 Pages

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 04, 2018 Report Length: 19 Pages

CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (Final)

DRUG PRODUCT INTERCHANGEABILITY AND PRICING ACT

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

GRADE Evidence Profiles on Long- and Rapid-Acting Insulin Analogues for the treatment of Diabetes Mellitus [DRAFT] October 2007

TITLE: Patient-Controlled Analgesia for Acute Injury Transfers: A Review of the Clinical Effectiveness, Safety, and Guidelines

FURNITURE TERMS / POLICIES. TERMS OF FURNITURE SALE [agreement is required with all orders] FURNITURE ORDERS

FINAL CDEC RECOMMENDATION

PLEASE NOTE. For more information concerning the history of this Act, please see the Table of Public Acts.

CADTH TECHNOLOGY REVIEW Community Water Fluoridation Programs: A Health Technology Assessment Review of Dental Caries and Other Health Outcomes

pan-canadian Oncology Drug Review Final Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer February 1, 2018

Service Line: Rapid Response Service Version: 1.0 Publication Date: August 31, 2018 Report Length: 10 Pages

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

pan-canadian Oncology Drug Review Initial Economic Guidance Report Osimertinib (Tagrisso) for Advanced or Metastatic Non-Small Cell Lung Cancer

CDEC FINAL RECOMMENDATION

pan-canadian Oncology Drug Review Initial Economic Guidance Report Fulvestrant (Faslodex) for Metastatic Breast Cancer November 30, 2017

CEDAC FINAL RECOMMENDATION

Service Line: Rapid Response Service Version: 1.0 Publication Date: July 19, 2017 Report Length: 66 Pages

FINAL CDEC RECOMMENDATION

SUMMARY OF perc DELIBERATIONS ON REQUEST FOR ADVICE

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

pan-canadian Oncology Drug Review Final Economic Guidance Report Ibrutinib (Imbruvica) for Mantle Cell Lymphoma July 19, 2016

Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Scientific Working Group on Digital Evidence

WALGREENS & RITE AID MERGER ANALYSIS

pan-canadian Oncology Drug Review Initial Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer May 5, 2016

PHYSIOTHERAPY ACT AUTHORIZATION REGULATIONS

CEDAC FINAL RECOMMENDATION

EVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT

pan-canadian Oncology Drug Review Final Economic Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016

pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018

pan-canadian Oncology Drug Review Final Economic Guidance Report Osimertinib (Tagrisso) for Non-Small Cell Lung Cancer January 4, 2019

SPECIAL DISCLAIMER FOR INTERPRETING SERVICES INVOLVING CALLS TO EMERGENCY SERVICE PROVIDERS (911/E911), OR LEGAL, MEDICAL OR MENTAL HEALTH ISSUES

CDEC FINAL RECOMMENDATION

Clinical Review Report

Health Interventions in Ambulatory Cancer Care Centres DRAFT. Objectives. Methods

Initial Recommendation for Ibrutinib (Imbruvica) for Mantle Cell Lymphoma perc Meeting: June 16, pcodr PAN-CANADIAN ONCOLOGY DRUG REVIEW 4

Coagulation Factor IX FC Fusion Protein (Alprolix): Treatment Cost Comparison and Budget Impact Analysis

Service Line: Rapid Response Service Version: 1.0 Publication Date: December 14, 2018 Report Length: 45 Pages

TITLE: Delivery of Electroconvulsive Therapy in Non-Hospital Settings: A Review of the Safety and Guidelines

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: Recommendations

DATE: 04 April 2012 CONTEXT AND POLICY ISSUES

Service Line: Rapid Response Service Version: 1.0 Publication Date: September 05, 2018 Report Length: 49 Pages

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

Tamsulosin Hydrochloride 0.4 mg Capsule

pan-canadian Oncology Drug Review Final Economic Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer July 16, 2015

Common Drug Review Pharmacoeconomic Review Report

pan-canadian Oncology Drug Review Initial Economic Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018

pan-canadian Oncology Drug Review Final Economic Guidance Report Palbociclib (Ibrance) for Advanced Breast Cancer Resubmission November 21, 2016

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

pan-canadian Oncology Drug Review Final Economic Guidance Report Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia March 2, 2018

Policies to Prevent Harms from the Co-Prescribing of Opioids and Central Nervous System Depressant Drugs

Transcription:

CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) GENERIC DRUG NAME (BRAND NAME) (Manufacturer) Indication: Text

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH. CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials. This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites. Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada s federal, provincial, or territorial governments or any third party supplier of information. This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user s own risk. This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada. The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors. About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system. Funding: CADTH receives funding from Canada s federal, provincial, and territorial governments, with the exception of Quebec. CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 2

Table of Contents Abbreviations... 4 Executive Summary... 5 Introduction... 5 Results and Interpretation... 5 Introduction... 6 Disease Prevalence and Incidence... 6 Standards of Therapy... 6 Drug... 6 Objectives and Methods... 7 Objectives... 7 Methods... 7 Results... 8 Findings from the Literature... 8 Included Studies... 9 Exposure to study treatments... 10 Critical Appraisal... 10 Efficacy... 10 Harms... 10 Discussion... 11 Summary of Available Evidence... 11 Interpretation of Results... 11 Conclusions... 11 Appendix 1: Patient Input Summary... 12 Appendix 2: Literature Search Strategy... 13 Appendix 3: Excluded Studies... 14 Appendix 4: Detailed Outcome Data... 15 Appendix 5: Validity Of Outcome Measures... 16 Appendix 6: Summary of Other Studies... 17 Appendix 7: Summary Of Indirect Comparisons... 18 CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 3

Abbreviations CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 4

Drug Indication Listing Request Manufacturer Executive Summary Introduction Results and Interpretation Included Studies Efficacy Harms Other Considerations Conclusions CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 5

Introduction Disease Prevalence and Incidence Standards of Therapy Drug CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 6

Objectives and Methods Objectives Methods Table 1: Inclusion criteria for the systematic review Patient Population Intervention Comparators Outcomes Study Design CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 7

Results Findings from the Literature Figure 1: Flow Diagram for Inclusion and Exclusion of Studies N Citations identified in literature search N Potentially relevant reports from other sources N Potentially relevant reports identified and screened N Total potentially relevant reports identified and screened N Reports excluded N Reports included Presenting data from N unique studies CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 8

DRUGS NOTES OUTCOMES DURATION POPULATIONS Table 2: Details of Included Studies DESIGNS & Study Design Locations Randomized (N) Inclusion Criteria Exclusion Criteria Study Name Study Name Intervention Comparator(s) Phase Run-in Double-blind Follow-up Primary End Point Other End Points Publications Included Studies Description of studies Populations Inclusion and exclusion criteria Baseline characteristics Interventions Outcomes Statistical analysis Analysis populations CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 9

Patient Disposition Exposure to study treatments Critical Appraisal Internal validity External validity Efficacy Key efficacy outcome 1 Key efficacy outcome 2 Other efficacy outcomes Harms Adverse events Serious adverse events Withdrawals due to adverse events Mortality Notable harms CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 10

Discussion Summary of Available Evidence Interpretation of Results Efficacy Harms Other Considerations Potential Place in Therapy 1 Conclusions 1 This information is based on information provided in draft form by the clinical expert consulted by CDR reviewers for the purpose of this review. CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 11

Appendix 1: Patient Input Summary CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 12

Appendix 2: Literature Search Strategy CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 13

Appendix 3: Excluded Studies Reference Reason for Exclusion CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 14

Appendix 4: Detailed Outcome Data CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 15

Appendix 5: Validity Of Outcome Measures CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 16

Appendix 6: Summary of Other Studies CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 17

Appendix 7: Summary Of Indirect Comparisons CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 18

References CADTH COMMON DRUG REVIEW Clinical Review Report (Sample) 19